13-Valent pneumococcal conjugate vaccine

Prescrire International

Volumn 20, Issue 112, 2011, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

13 VALENT PNEUMOCOCCUS CONJUGATE VACCINE; 7 VALENT PNEUMOCOCCUS CONJUGATE VACCINE; ANTIPYRETIC AGENT; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE; POLYSORBATE 80; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; ERYTHEMA; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; PNEUMOCOCCAL INFECTION; REVIEW; SEROTYPE; SLEEP DISORDER; VACCINATION;

CHILD, PRESCHOOL; EUROPEAN UNION; EXCIPIENTS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSORBATES; VACCINES, CONJUGATE;

EID: 78651230835     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (3)

1. European Medicines Agency - CHMP "European Public Assessment Report (first published) - Prevenar 13. Scientific discussion no 1104" 61 pages, posted on EMA website 9 December 2009.
2. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "FDA Briefing Document Prevnar 13" 18 November 2009: 61 pages.
3. European Commission "Summary of Product Characteristics - Prevenar 13" 9 December 2009: 13 pages.